Daratumumab interference with immunohematology testing in a nonmultiple myeloma neutropenic patient, in need of granulocyte transfusion

Daratumumab (DARA) may interfere with immunohematology tests by binding to endogenous CD38 present on the surface of the red blood cells. DARA was Food and Drug Administration approved for refractory multiple myeloma patients, but now its application is being explored in other oncology patients also...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Abhaykumar Malind Gupta, Shashank Ojha, Amol Tirlotkar, Vimal Sathyan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wolters Kluwer Medknow Publications 2021-01-01
coleção:	Global Journal of Transfusion Medicine
Assuntos:	anti-cd38 compatibility testing daratumumab dithiothreitol serology interference
Acesso em linha:	http://www.gjtmonline.com/article.asp?issn=2468-8398;year=2021;volume=6;issue=1;spage=103;epage=105;aulast=Gupta
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!